Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 4/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16528900 | 0.96 | JAK3 (0.44) | JAK3GRIN2BGRIN2CSOS1SOS2 | |
| SCHEMBL22481424 | 0.94 | JAK3 (0.40) | JAK3GRIN2BGRIN2CSOS1SOS2 | |
| SCHEMBL31450504 | 0.94 | JAK3 (0.42) | JAK3GRIN2BGRIN2CSOS1SOS2 | |
| SCHEMBL34473824 | 0.94 | JAK3 (0.42) | JAK3GRIN2BGRIN2CSOS1SOS2 | |
| SCHEMBL1771960 | 0.94 | JAK3 (0.42) | JAK3GRIN2BGRIN2CSOS1SOS2 | |
| SCHEMBL1555738 | 0.90 | JAK3 (0.44) | JAK3GRIN2BGRIN2CSOS1SOS2 | |
| SCHEMBL22169129 | 0.90 | SOS1 (0.41) | JAK3GRIN2BGRIN2CSOS1SOS2 | |
| SCHEMBL10277023 | 0.90 | SOS1 (0.45) | JAK3GRIN2BGRIN2CSOS1SOS2 | |
| SCHEMBL18340068 | 0.89 | JAK3 (0.44) | JAK3GRIN2BGRIN2CSPRUSP2 | |
| SCHEMBL4910509 | 0.88 | SOS1 (0.44) | JAK3GRIN2BGRIN2CSOS1SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174674-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) | 2024-05-30 | — | — | US | disclosed |
| US-20240150367-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-114907338-B | Nitrogen-containing polycyclic condensed ring compound, pharmaceutical composition, preparation method and application thereof | 北京志健金瑞生物医药科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4289428-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Applied Pharmaceutical Science, Inc. (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-111278840-B | Pyrrolo [2,3-B ] pyridine compounds and their use for the treatment of cancer | 癌症研究科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230023377-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230023377-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-26 | — | — | US | disclosed |
| WO-2022166642-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 北京志健金瑞生物医药科技有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2022140390-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20140187534-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140187534-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140187534-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-8609647-B2 | Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof | JAPAN TOBACCO INC. (JP) | 2013-12-17 | — | — | US | disclosed |
| WO-2013066718-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2460806-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| EP-2460806-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NR3C2 | JAK3 899/4885GRIN2B 2949/4885GRIN2C 2718/4885 |
| US-20230023377-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NPR1 | JAK3 570/4885GRIN2B 3350/4885GRIN2C 3978/4885 |
| US-20140187534-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NR3C2 | JAK3 899/4885GRIN2B 2949/4885GRIN2C 2718/4885 |
| US-20240150367-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, NPR1 | JAK3 504/4885GRIN2B 3458/4885GRIN2C 4028/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | JAK3 1400/4885GRIN2B 1631/4885GRIN2C 861/4885 |
| US-20240174674-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | RET, WEE1, JAK2 | JAK3 28/4885GRIN2B 2960/4885GRIN2C 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.